ProPhase Labs, Inc.

NasdaqCM:PRPH Rapporto sulle azioni

Cap. di mercato: US$18.3m

ProPhase Labs Gestione

Gestione criteri di controllo 1/4

ProPhase Labs Il CEO è Ted Karkus, nominato in Jun2009, e ha un mandato di 15.42 anni. la retribuzione annua totale è $ 3.37M, composta da 20% di stipendio e 80% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 13.47% delle azioni della società, per un valore di $ 2.46M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 15.4 anni.

Informazioni chiave

Ted Karkus

Amministratore delegato

US$3.4m

Compenso totale

Percentuale dello stipendio del CEO20.0%
Mandato del CEO15.4yrs
Proprietà del CEO13.5%
Durata media del managementless than a year
Durata media del Consiglio di amministrazione15.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

Nov 09
Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

Nov 09
It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03
Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09
ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21
ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11
Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07
We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Jan 24
ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

Oct 13

ProPhase Labs Q2 2022 Earnings Preview

Aug 10

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Jul 26
We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ted Karkus rispetto agli utili di ProPhase Labs?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$3mUS$675k

-US$17m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

US$7m

Dec 31 2022US$902kUS$675k

US$18m

Sep 30 2022n/an/a

US$31m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$18m

Dec 31 2021US$941kUS$590k

US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$460k

Dec 31 2020US$445kUS$125k

-US$2m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$249kUS$125k

-US$3m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$2mUS$210k

-US$2m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$826k

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$2mUS$675k

-US$2m

Compensazione vs Mercato: La retribuzione totale di Ted ($USD 3.37M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 652.28K ).

Compensazione vs guadagni: La retribuzione di Ted è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Ted Karkus (65 yo)

15.4yrs

Mandato

US$3,367,200

Compensazione

Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Ted Karkus
Chairman & CEO15.4yrsUS$3.37m13.47%
$ 2.5m
Jed Latkin
Chief Operating Officer & Head of Finance Departmentless than a yearNessun datoNessun dato
Sergio Miralles
Executive VP & Chief Information Officerless than a yearNessun datoNessun dato
Kamal Obbad
Senior VP and Director of Sales & Marketing - Nebula Genomics1.8yrsNessun datoNessun dato
Jason Karkus
President of Nebula Genomicsless than a yearNessun datoNessun dato
Lance Bisesar
Corporate Controllerless than a yearNessun datoNessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di PRPH non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Ted Karkus
Chairman & CEO15.4yrsUS$3.37m13.47%
$ 2.5m
Louis Gleckel
Independent Director15.4yrsUS$223.00k0.43%
$ 79.4k
Warren Hirsch
Independent Director5.5yrsUS$223.00k0%
$ 0

15.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PRPH è composto da personale esperto e esperto (durata media dell'incarico 15.4 anni).